HK1051533A1 - Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use. - Google Patents

Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use.

Info

Publication number
HK1051533A1
HK1051533A1 HK03103726A HK03103726A HK1051533A1 HK 1051533 A1 HK1051533 A1 HK 1051533A1 HK 03103726 A HK03103726 A HK 03103726A HK 03103726 A HK03103726 A HK 03103726A HK 1051533 A1 HK1051533 A1 HK 1051533A1
Authority
HK
Hong Kong
Prior art keywords
pyridine
ylamino
diaryl
substituted
production
Prior art date
Application number
HK03103726A
Other languages
English (en)
Inventor
Reinhard Kirsch
Alfons Enhsen
Heiner Glombik
Werner Kramer
Eugen Falk
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of HK1051533A1 publication Critical patent/HK1051533A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK03103726A 1998-10-02 2003-05-27 Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use. HK1051533A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845406A DE19845406C2 (de) 1998-10-02 1998-10-02 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006933 WO2000020393A1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
HK1051533A1 true HK1051533A1 (en) 2003-08-08

Family

ID=7883187

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103726A HK1051533A1 (en) 1998-10-02 2003-05-27 Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use.

Country Status (23)

Country Link
US (1) US6596728B1 (zh)
EP (1) EP1117642B1 (zh)
JP (1) JP4544746B2 (zh)
KR (1) KR100609255B1 (zh)
CN (1) CN1173951C (zh)
AR (1) AR021845A1 (zh)
AT (1) ATE267809T1 (zh)
AU (1) AU757689B2 (zh)
BR (1) BR9915027B1 (zh)
CA (1) CA2345985C (zh)
CZ (1) CZ299569B6 (zh)
DE (2) DE19845406C2 (zh)
DK (1) DK1117642T3 (zh)
ES (1) ES2219066T3 (zh)
HK (1) HK1051533A1 (zh)
HU (1) HU226688B1 (zh)
ID (1) ID29249A (zh)
PL (1) PL205034B1 (zh)
PT (1) PT1117642E (zh)
RU (1) RU2224748C2 (zh)
TR (1) TR200100896T2 (zh)
WO (1) WO2000020393A1 (zh)
ZA (1) ZA200102587B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231688A1 (en) 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
PL366855A1 (en) * 2001-08-22 2005-02-07 Aventis Pharma Deutschland Gmbh Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
BR112015023697A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de esôfago de barrett e doença do refluxo gastroesofágico
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
ES2223091T3 (es) * 1997-04-04 2005-02-16 Aventis Pharma Deutschland Gmbh Derivados de propanolamina hipolipidemicos.
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung

Also Published As

Publication number Publication date
HU226688B1 (hu) 2009-06-29
AU757689B2 (en) 2003-03-06
CZ299569B6 (cs) 2008-09-03
CN1391558A (zh) 2003-01-15
RU2224748C2 (ru) 2004-02-27
EP1117642A1 (de) 2001-07-25
CN1173951C (zh) 2004-11-03
TR200100896T2 (tr) 2001-09-21
ES2219066T3 (es) 2004-11-16
US6596728B1 (en) 2003-07-22
CA2345985C (en) 2010-06-29
JP4544746B2 (ja) 2010-09-15
JP2002526530A (ja) 2002-08-20
DE59909606D1 (de) 2004-07-01
DE19845406C2 (de) 2001-10-18
DE19845406A1 (de) 2000-04-13
ID29249A (id) 2001-08-16
AU6192699A (en) 2000-04-26
ATE267809T1 (de) 2004-06-15
WO2000020393A1 (de) 2000-04-13
AR021845A1 (es) 2002-08-07
KR100609255B1 (ko) 2006-08-04
DK1117642T3 (da) 2004-08-09
BR9915027B1 (pt) 2010-09-08
PT1117642E (pt) 2004-09-30
CA2345985A1 (en) 2000-04-13
CZ20011152A3 (cs) 2001-07-11
PL347096A1 (en) 2002-03-25
BR9915027A (pt) 2001-07-17
EP1117642B1 (de) 2004-05-26
KR20010075496A (ko) 2001-08-09
PL205034B1 (pl) 2010-03-31
HUP0103533A3 (en) 2003-01-28
ZA200102587B (en) 2001-11-05
HUP0103533A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
HUP0200312A3 (en) Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP0105073A3 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
HUP0203496A3 (en) Novel cyclopropane derivatives, pharmaceutical compositions containing them and method for the production thereof
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HUP9803040A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
IL143577A0 (en) Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA200102589B (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof.
HUP0105075A3 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives, their use and pharmaceutical compositions containing them
HK1051533A1 (en) Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use.
ZA99355B (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them.
HU9700955D0 (en) Substituted 2-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them
HUP0200928A3 (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
IL139531A0 (en) Human antithrombin iii, methods for the production thereof and pharmaceutical compositions containing the same
EP1059304A4 (en) NOVEL POLYSACCHARIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITIONS CONTAINING THESE NEW DERIVATIVES AS ACTIVE INGREDIENT
HUP0004457A3 (en) Angiogenesis inhibiting thiadiazolyl-pyridazine derivatives, process for producing them and pharmaceutical compositions containing the same
HU9700954D0 (en) Substituted 1-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them
HU9900263D0 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
AU3076600A (en) 3,7-disubstituted indole derivatives and medicinal compositions containing the same
IL146812A0 (en) Streptogramin derivatives, production thereof and compositions containing the same
HUP9803041A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
HUP0105104A3 (en) Novel polyhydroxypyrazine derivatives, pharmaceutical compositions containing same and their producing

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150918